Marketwatch, July 13, 2021: Fees paid by drug companies make up half of the FDA’s revenue. Dr. Diana Zuckerman explains how these fees often influence FDA decisions and sacrifice patient safety.
Read More »Tag: FDA
Drug Prices Are One Focus of Biden’s Push to Boost Competition
Wall Street Journal, July 9, 2021: Drug prices in the US are extremely high with both sides of the aisle advocating for Medicare to be able to negotiate drug prices. Dr. Diana Zuckerman spoke with the WSJ about how President Biden plans to lower drug prices.
Read More »Scientific Coalition Letter on Aduhelm to HHS Inspector General, CMS, and Congress
July 7, 2021. As organizations working to promote and protect science for the public good, we are writing to express our concern about the lack of scientific evidence to support the FDA’s recent accelerated approval of Biogen’s Aduhelm (aducanumab) as a drug intended to slow cognitive damage caused by Alzheimer’s disease.
Read More »Emergency Use Authorization vs. Full Approval: What are the Implications?
Contagion Live, June 20, 2021: What is the difference between Emergency Use Authorization and FDA Approval? Dr. Diana Zuckerman addresses the difference between the two and the implications of both.
Read More »New Alzheimer’s drug could be ‘devastating’ for Medicare
Politico, June 15, 2021: The controversial approval of the first drug to target Alzheimer’s disease in nearly 20 years has been blasted by many experts, because the drug is not proven to work and will cost $56,000 per year. “You don’t have to be a rocket scientist to know that the impact on Medicare is likely to be devastating,” said Diana Zuckerman, the president of the National Center for Health Research.
Read More »